Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aerovance, Inc.
Market Snapshot: GSK's Blenrep and BMS's Abecma are the first of many drugs for the late-line setting. In many cases, the CAR-T may be the first choice, but some patients are unable to handle it or risk progressing while awaiting treatment.
Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.
The company’s first candidate is a BCMA-targeting CAR-T, but Arcellx also is developing ARC T-cells controlled by a synthetic protein. Both have a binding domain that may confer better safety and efficacy than competitors.
Keeping Track: Cloudy Horizon For Teplizumab, Roxadustat; Nuplazid Stumbles Over Subgroups; CAR-T Submissions From Gilead, J&J
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Large Molecule